Posted on 2/25/2019
France-based medtech company Affluent Medical has announced positive results from its SCOPE 1 clinical trial validating the efficacy of Kardiozis technology: an endoprosthesis using thrombogenic fibre embolisation of the aneurysm sac to prevent endoleak and reintervention.
The results were presented at the Controversies And Updates in Vascular Surgery congress (CACVS; 7–9 February, Paris, France) by principal investigator Dominique Fabre. Study contributors include Frederic Cochennec, Claude Angel, Eric Allaire, Philippe Brenot, Riyad Bourkaib Jean-Yves Riou, Pascal Desgranges, Benoit Gerardin, Delphine Mitilian, Carlos Garcia Alonzo, Sara...